{"id":760488,"date":"2026-04-29T04:02:29","date_gmt":"2026-04-29T04:02:29","guid":{"rendered":"https:\/\/www.europesays.com\/us\/760488\/"},"modified":"2026-04-29T04:02:29","modified_gmt":"2026-04-29T04:02:29","slug":"assessing-revolution-medicines-rvmd-valuation-after-positive-rasolute-302-and-zoldonrasib-clinical-updates","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/760488\/","title":{"rendered":"Assessing Revolution Medicines (RVMD) Valuation After Positive RASolute 302 And Zoldonrasib Clinical Updates"},"content":{"rendered":"\n

Get insights on thousands of stocks<\/a> from the global community of over 7 million individual investors at Simply Wall St.<\/p>\n

Clinical catalysts and pipeline momentum behind Revolution Medicines stock <\/p>\n

Revolution Medicines (RVMD) is in focus after reporting statistically significant Phase 3 RASolute 302 data for daraxonrasib in metastatic pancreatic cancer, alongside updated early stage results for zoldonrasib in KRAS G12D non small cell lung cancer.<\/p>\n

See our latest analysis for Revolution Medicines.<\/a><\/p>\n

Despite the latest 1 day share price return of negative 2.68% and a 7 day share price return of negative 9.96%, Revolution Medicines has a 30 day share price return of 42.33%, a year to date share price return of 66.63% and a 1 year total shareholder return of 217.51%. This suggests strong momentum around the recent daraxonrasib and zoldonrasib updates and growing attention on its late stage pipeline.<\/p>\n

If this kind of clinical news has your attention, it can be useful to see what else is moving in related areas, including 32 healthcare AI stocks<\/a><\/p>\n

With Revolution Medicines now a roughly US$28.5b pre-revenue company, and the stock up 217.51% over 1 year and 66.63% year to date, the key question is whether this clinical success story is still an opportunity or if markets are already pricing in future growth.<\/p>\n

Most Popular Narrative: 150% Undervalued <\/p>\n

The most followed narrative places Revolution Medicines’ fair value at $133.70, just above the last close of $131.67, and ties that gap to ambitious long term growth and margin targets.<\/p>\n

\n

The move toward targeted oncology treatments for high unmet need tumors such as pancreatic, lung and colorectal cancer aligns with the company\u2019s RAS(ON) portfolio, which could influence long term revenue growth if multiple registrational programs convert to approved therapies.<\/p>\n<\/blockquote>\n

Read the complete narrative.<\/a><\/p>\n

Curious what sits behind that valuation gap. The narrative leans heavily on rapid revenue expansion, margin improvement and a rich future earnings multiple. Want the full set of assumptions that tie those pieces together.<\/p>\n

Result: Fair Value of $133.70 (UNDERVALUED)<\/strong><\/p>\n

Have a read of the narrative in full and understand what’s behind the forecasts.<\/a><\/p>\n

However, this story can change quickly if the late stage RAS program stumbles in key trials or if heavy 2026 operating costs strain that cash cushion faster than expected.<\/p>\n

Find out about the key risks to this Revolution Medicines narrative.<\/a><\/p>\n

Another View: Rich P\/B Raises the Bar <\/p>\n

The earlier story leans on future cash flows and suggests Revolution Medicines is trading below an estimated fair value of $351.35. In contrast, the current P\/B of 17x is far higher than the US Biotechs industry at 2.4x and peers at 10.1x. This points to a lot already priced in and raises the question of how much execution risk you are willing to accept at this level.<\/p>\n

See what the numbers say about this price \u2014 find out in our valuation breakdown.<\/a><\/p>\n

\"NasdaqGS:RVMD<\/a> NasdaqGS:RVMD P\/B Ratio as at Apr 2026 Next Steps <\/p>\n

Given the mix of excitement and caution in this story, it makes sense to review the numbers yourself and decide promptly where you stand by weighing the 2 key rewards and 3 important warning signs<\/a>.<\/p>\n

Looking for more investment ideas? <\/p>\n

If you are serious about building a stronger portfolio, it makes sense to look beyond a single story and line up a few more quality candidates.<\/p>\n

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.<\/strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.<\/p>\n

Companies discussed in this article include RVMD<\/a>.<\/p>\n

Have feedback on this article? Concerned about the content? Get in touch<\/a> with us directly.<\/strong> Alternatively, email editorial-team@simplywallst.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply…\n","protected":false},"author":3,"featured_media":507944,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[55968,210,1060,312458,312459,67,132,68],"class_list":{"0":"post-760488","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-fair-value","9":"tag-health","10":"tag-medication","11":"tag-metastatic-pancreatic-cancer","12":"tag-total-shareholder-return","13":"tag-united-states","14":"tag-unitedstates","15":"tag-us"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/116486009456093704","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/760488","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=760488"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/760488\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/507944"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=760488"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=760488"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=760488"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}